Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/08/24
Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/08/24
Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible UrticariaGlobeNewsWire • 07/29/24
Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous UrticariaGlobeNewsWire • 07/16/24
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024GlobeNewsWire • 06/02/24
Wall Street Analysts Think Celldex (CLDX) Could Surge 87.27%: Read This Before Placing a BetZacks Investment Research • 05/27/24
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo NodularisGlobeNewsWire • 05/15/24
Wall Street Analysts Believe Celldex (CLDX) Could Rally 67.77%: Here's is How to TradeZacks Investment Research • 05/09/24
Celldex Reports First Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/06/24
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible UrticariaGlobeNewsWire • 04/17/24
Down -14.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)Zacks Investment Research • 04/09/24
Down -17.39% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)Zacks Investment Research • 04/08/24
Does Celldex (CLDX) Have the Potential to Rally 71.82% as Wall Street Analysts Expect?Zacks Investment Research • 03/20/24
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma ConferenceGlobeNewsWire • 03/08/24
Celldex Therapeutics to Present at TD Cowen's 44th Annual Health Care ConferenceGlobeNewsWire • 03/05/24
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 03/05/24
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common StockGlobeNewsWire • 03/01/24
Wall Street Analysts Predict a 26.53% Upside in Celldex (CLDX): Here's What You Should KnowZacks Investment Research • 02/29/24
Celldex Therapeutics (CLDX) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 02/26/24
Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 02/26/24